Estradiol Tablet
NDC Package 70518-2829-0
Package Information
Estradiol tablets is a medication a female hormone. This formulation utilizes a tablet delivery system. Marketed by Remedyrepack Inc., this product is identified by NDC 70518-2829 and is authorized under FDA application ANDA040275.
Identification & Billing
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 70518 - Remedyrepack Inc.
- 70518-2829 - Estradiol
- 70518-2829-0 - 100 POUCH in 1 BOX / 1 TABLET in 1 POUCH (70518-2829-1)
- 70518-2829 - Estradiol
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 70518-2829-0 identifies a specific commercial package of 100 pouch in 1 box / 1 tablet in 1 pouch (70518-2829-1) of Estradiol, a human prescription drug labeled by Remedyrepack Inc.. This tablet is formulated for oral use and contains estradiol as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Remedyrepack Inc. on August 07, 2020. The current certification is valid through December 31, 2027.
What are the primary indications for this medication?
This medication is a female hormone. It is used by women to help reduce symptoms of menopause (such as hot flashes, vaginal dryness). These symptoms are caused by the body making less estrogen. If you are using this medication to treat symptoms only in and around the vagina, products applied directly inside the vagina should be considered before medications that are taken by mouth, absorbed through the skin, or injected. Certain estrogen products may also be used by women after menopause to prevent bone loss (osteoporosis). However, there are other medications (such as raloxifene, bisphosphonates including alendronate) that are also effective in preventing bone loss and may be safer. These medications should be considered for use before estrogen treatment. Certain estrogen products may also be used by men and women to treat cancers (certain types of prostate cancer, breast cancer that has spread to other parts of the body) and by women who are not able to produce enough estrogen (for example, due to hypogonadism, primary ovarian failure).
How is this Remedyrepack Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 70518282900. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.